Beth mae “Clir” yn ei olygu?
Nid yw'r anifail yn cario'r treiglad. Ni fydd yn datblygu'r afiechyd ac ni fydd yn ei drosglwyddo.
Cath Alffa Mannosidosis (AlphaMan)
Alpha Mannosidosis (AlphaMan) is a rare genetic disorder affecting cats, caused by a deficiency of the enzyme alpha-mannosidase. This DNA test helps identify carriers and affected cats, enabling responsible breeding decisions to prevent the spread of the disease. Early detection through the Alpha Mannosidosis DNA test is crucial for managing symptoms and improving feline health. By screening your cat, you contribute to reducing the incidence of AlphaMan in future generations. Trusted by veterinarians and breeders, this test provides accurate and reliable results. Ensure your cat’s well-being with the Alpha Mannosidosis DNA test today. Protect your feline companion from hereditary health risks with this essential genetic screening.
Talfyriad: AlphaMan
Treiglad wedi'i ddadansoddi : MAN2B1 c.1749_1752del
Etifeddiaeth: Autosomal Reciliol
Acronym
AlphaMan
Amlder a arsylwyd
Difrifoldeb clinigol
Dosbarthiad clinigol
Clefydau Metabolaidd
Treiglad wedi'i ddadansoddi
MAN2B1 c.1749_1752del
p.(Q584Afs)
p.(Q584Afs)
Modd etifeddiaeth
Autosomal Reciliol
Crynodeb prawf:
Alpha Mannosidosis (AlphaMan) is a rare genetic disorder in cats caused by a deficiency of the enzyme alpha-mannosidase. This leads to the accumulation of complex sugars in cells, resulting in progressive neurological and physical symptoms. A DNA test for AlphaMan helps identify carriers and affected cats, enabling responsible breeding decisions. Early detection through testing can improve management and care for affected cats. Genetic screening is essential to reduce the incidence of this debilitating condition in feline populations.
Ar gael o'r pecyn: Basic
Mae'r prawf DNA hwn wedi'i gynnwys gan ddechrau o'n pecyn Basic - ac mae hefyd yn rhan o'r pecynnau Basic, Standard, Advanced, Complete.
Gweld Pecynnau Prawf DNA →Dewiswch y pecyn sy'n gweddu orau i'ch strategaeth bridio neu iechyd eich anifeiliaid.
Understanding Alpha Mannosidosis in Cats
Alpha Mannosidosis (AlphaMan) is a rare genetic disorder that affects the metabolism of certain sugars in the body. It is caused by a deficiency in the enzyme alpha-mannosidase, which is responsible for breaking down mannose-containing oligosaccharides. When this enzyme is deficient or absent, these sugars accumulate in the body's cells, leading to a range of health issues.
Symptoms and Clinical Manifestations
Cats with Alpha Mannosidosis may exhibit a variety of clinical symptoms that can vary in severity. Common signs include neurological deficits, such as poor coordination, muscle weakness, and behavioral changes. Additionally, affected cats might experience growth delays, skeletal abnormalities, and impaired immune function. The onset of symptoms can occur at different ages, often leading to a progressive decline in health over time.
Diagnosis of Alpha Mannosidosis
Diagnosing Alpha Mannosidosis typically involves a combination of clinical evaluation and laboratory testing. A veterinarian will assess the cat's medical history and symptoms, followed by conducting biochemical tests to measure enzyme activity. Genetic testing through DNA analysis can confirm the presence of mutations in the gene responsible for encoding the alpha-mannosidase enzyme, providing a definitive diagnosis.
Opsiynau Rheoli a Thrin
Currently, there is no cure for Alpha Mannosidosis, and treatment is primarily supportive. Management strategies may include symptomatic care to improve the quality of life for affected cats. This can involve nutritional support, physical therapy, and regular veterinary check-ups to monitor the animal's condition. Research is ongoing to explore potential therapeutic options, including enzyme replacement therapy and gene therapy, which may offer hope for future treatments.
The Importance of Genetic Testing
Genetic testing for Alpha Mannosidosis is crucial for breeders and pet owners to identify carriers of the gene mutation and prevent the propagation of this disorder. By understanding the genetic status of their cats, responsible breeding practices can be implemented to reduce the risk of this condition in future generations. Additionally, early detection through DNA testing can help owners make informed decisions regarding the health management of their pets.
Brid yn cael ei gydnabod ar gyfer y prawf: Alffa Mannosidosis (AlphaMan)
- Persian
🧬 Interpretation of genotypes AlphaMan
Genoteip
Statws
🟡 N/N
Heb fod yn gludwr - Dim Risg
🟡 N/AlphaMan
Cludwr - Dim Risg
❌ AlphaMan/AlphaMan
Wedi'i Effeithio - Mewn Perygl
FAQ: deall y dehongliad
Ydy “Cludwr” yn ddifrifol?
Mae'r anifail yn gyffredinol iach ond gall drosglwyddo'r treiglad iddo epil.
Beth os yw anifail yn cael ei “Effeithio”?
Mae'n cario dau gopi treigledig. Disgwylir arwyddion clinigol yn dibynnu ar y clefyd. Ni ddylid ei fridio.
Pam mae gwahaniaethau rhwng gwryw / benyw?
Mae rhai afiechydon yn gysylltiedig â rhyw, felly mae eu mynegiant yn amrywio yn dibynnu ar y rhyw anifail.
Rhagfynegi Epil
N/N (heb-fod-yn-gludwr)
N/AlphaMan (Cludwr)
AlphaMan/AlphaMan (Wedi'i effeithio)
Cwestiynau Cyffredin Prawf DNA
Beth mae'r prawf DNA hwn yn ei ganfod?
This DNA test detects the mutation associated with Alpha Mannosidosis (AlphaMan) in order to identify clear, carrier, or at-risk animals.
Pam rhoi prawf ar anifail magu?
Mae profion DNA yn helpu bridwyr i gynllunio paru mwy diogel a lleihau'r risg o drosglwyddo'r mwtaniad i'r epil.
Beth yw modd etifeddiaeth y prawf hwn?
Y modd etifeddu a adroddwyd ar gyfer y prawf hwn yw Autosomal Recessive.
Pa dreiglad sy'n cael ei ddadansoddi yn y prawf hwn?
This test analyses the mutation MAN2B1 c.1749_1752del.
A effeithir ar anifail cludo o reidrwydd?
Ddim o reidrwydd. Mae dehongliad yn dibynnu ar y patrwm etifeddiaeth a'r genoteip canlyniadol.
Cyfeiriadau
Berg T, Tollersrud O K, Walkley S U, Siegel D, Nilssen O. Purification of feline lysosomal alpha-mannosidase, determination of its cDNA sequence and identification of a mutation causing alpha-mannosidosis in Persian cats. Biochem J. 1997 Dec 15;328 ( Pt 3)(Pt 3):863-70. doi: 10.1042/bj3280863.